Navigation Links
Oncolytics Biotech(R) Inc. Announces Start of Enrolment in U.S. Phase 2 Melanoma Cancer Clinical Trial
Date:9/24/2009

CALGARY, Sept. 24 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ: ONCY) announced today that the Cancer Therapy Research Center at the University of Texas Health Science Center (CTRC) has started patient enrolment in a U.S. Phase 2 clinical trial using intravenous administration of REOLYSIN(R) in combination with paclitaxel and carboplatin in patients with metastatic melanoma. The Principal Investigator is Dr. Devalingam Mahalingam, M.D., Ph.D., MRCP(UK), MRCP(I), clinical investigator in GI/thoracic oncology and drug development at the CTRC.

"We have seen some very encouraging results in our clinical trials using REOLYSIN in combination with other therapies in metastatic melanoma patients," said Dr. Brad Thompson, President and CEO of Oncolytics. "For example, of nine evaluable melanoma patients treated intravenously in our combination REOLYSIN and chemotherapy trials, five had stable disease or better (two partial responses and three stable disease).

"In our local administration REOLYSIN and radiation studies, all of the evaluable melanoma patients (10) had stable disease or better in the target lesion, (three partial responses, one significant minor response and six stable disease). These results, combined with preclinical work demonstrating that in vivo combination treatment resulted in markedly reduced tumour growth compared to single agent treatments, provided the rationale for our collaborators to explore a Phase 2 combination study for patients with metastatic melanoma."

"Today, few effective treatment options exist for patients with advanced malignant melanoma," said Dr. Mahalingam. "We welcome this collaboration with Oncolytics, and are excited to have started patient enrolment for this Phase II investigator-initiated study at the CTRC. We are hopeful this no
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Oncolytics Biotech Inc. Announces Start of Patient Enrolment in Translational Clinical Trial Investigating REOLYSIN(R) in Patients with Metastatic Colorectal Cancer
2. Cancer Therapy & Research Center at The University of Texas Health Science Center and Oncolytics Biotech(R) Inc. Announce Multi-Trial Clinical Research Collaboration
3. Oncolytics Biotech(R) Inc. Announces Start of Enrolment in U.S. Phase 2 Combination Clinical Trial for Non-Small Cell Lung Cancer Patients with K-RAS or EGFR-Activated Tumours
4. Oncolytics Biotech(R) Inc. Announces Publication of Research on Synergistic Activity of Reovirus and Chemotherapy in NSCLC
5. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
6. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
7. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
8. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
9. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
10. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
11. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... 2015  AVACEN, Inc. announced today the issue by the ... medical technology platform supporting its unique Dry Heat Therapy AVACEN ... Logo - http://photos.prnewswire.com/prnh/20150630/227364LOGO ... 9,066,781 - Methods And Apparatus For Therapeutic Application of Thermal ... methods of use, referred to by the company as the ...
(Date:7/1/2015)... 1, 2015 Radiant Insights announce ... Oxygen Concentrators Market Shares, Strategy, and Forecasts, Worldwide, ... continuing growth as the aging population worldwide needs homecare ... conditions where oxygen is able to improve the quality ... have become affordable and support a mobile lifestyle even ...
(Date:7/1/2015)... , July 1, 2015 ... is expected to reach USD 49,119.2 million by 2020, ... Inc. Monitoring services is expected to remain the dominant ... USD 1,227.5 million in 2012, and an estimated CAGR ... (Logo: http://photos.prnewswire.com/prnh/20150105/723757 ) , Browse full ...
Breaking Medicine Technology:AVACEN Medical Patent Issued 2Stationary Oxygen Concentrators Market to Reach $2 Billion by 2021: Radiant Insights, Inc. 2Stationary Oxygen Concentrators Market to Reach $2 Billion by 2021: Radiant Insights, Inc. 3Stationary Oxygen Concentrators Market to Reach $2 Billion by 2021: Radiant Insights, Inc. 4mHealth Market Worth $ 49,119.2 Million By 2020: Grand View Research, Inc. 2mHealth Market Worth $ 49,119.2 Million By 2020: Grand View Research, Inc. 3mHealth Market Worth $ 49,119.2 Million By 2020: Grand View Research, Inc. 4mHealth Market Worth $ 49,119.2 Million By 2020: Grand View Research, Inc. 5
... following statement,by Andrea Kavanagh, Director of the Pure Salmon ... publish a study tomorrow that,shows sea lice from open ... wild fish stocks., "This study confirms what we ... havoc on wild salmon populations. If outbreaks of these,parasites ...
... Results, SOUTH SAN FRANCICSO, Calif., Dec. 13 ... announced that its oral syk,kinase inhibitor, R788 (tamatinib ... Arthritis (RA) patients in a,recently completed Phase 2 ... 150mg po bid (orally, twice daily), showed higher ...
Cached Medicine Technology:Rigel's R788 Demonstrates Significant Improvement in Rheumatoid Arthritis in Phase 2 Clinical Study 2Rigel's R788 Demonstrates Significant Improvement in Rheumatoid Arthritis in Phase 2 Clinical Study 3Rigel's R788 Demonstrates Significant Improvement in Rheumatoid Arthritis in Phase 2 Clinical Study 4Rigel's R788 Demonstrates Significant Improvement in Rheumatoid Arthritis in Phase 2 Clinical Study 5Rigel's R788 Demonstrates Significant Improvement in Rheumatoid Arthritis in Phase 2 Clinical Study 6
(Date:7/1/2015)... ... July 01, 2015 , ... ... software products, announced today that it has received trademark protection for its SensorInsight® ... detailed analysis of data from multiple sources providing an environment where users can ...
(Date:7/1/2015)... ... July 01, 2015 , ... Amada Senior Care, premier provider ... in the greater Phoenix area – their Mesa, Arizona location . Amada franchise ... with their purchase of the rights to the area after years of experience in ...
(Date:7/1/2015)... Bethlehem, PA (PRWEB) , ... July 01, 2015 , ... ... seek meaning and purpose in life with a healthy balance between work and life, ... do this in her new book, Positive Health: Flourishing Lives, Wellbeing in Doctors. , ...
(Date:7/1/2015)... Newport Beach, CA (PRWEB) , ... July 01, ... ... Orrick has returned to the Northbound team as Director of Referral Relations. ... two programs, including Northbound’s Collegebound, where she designed and implemented unique academic curriculum ...
(Date:7/1/2015)... ... July 01, 2015 , ... AvePoint, the ... opening of a new operational office in Zurich, Switzerland. The new facility will ... lines of business for organizations throughout the Swiss market. , “AvePoint is ...
Breaking Medicine News(10 mins):Health News:Element Blue Receives Trademark Protection from U.S. Patent and Trademark Office for Its Award Winning SensorInsight® Software 2Health News:Element Blue Receives Trademark Protection from U.S. Patent and Trademark Office for Its Award Winning SensorInsight® Software 3Health News:Element Blue Receives Trademark Protection from U.S. Patent and Trademark Office for Its Award Winning SensorInsight® Software 4Health News:Amada Senior Care Expands to Greater Phoenix Area 2Health News:Medical Doctor Explains The Healthy Effects of a Positive Outlook in New Book 2Health News:Northbound Treatment Services Welcomes Emily Orrick as Director of Referral Relations 2Health News:AvePoint Opens Office in Zurich to Meet Increasing Market Demand for Enterprise Collaboration Solutions in Switzerland 2Health News:AvePoint Opens Office in Zurich to Meet Increasing Market Demand for Enterprise Collaboration Solutions in Switzerland 3
... is a risk factor for breast cancer development. However, ... ,These ER-alphanegative cancers are more aggressive and ... and have been thought to be estrogen independent. ... in advance of publication in the August print issue ...
... of the most renowned church leaders in Lesotho have signed ... the country, the UN Action Against AIDS (UNAIDS) said ... tragic toll of the AIDS epidemic, brings compelling urgency to ... achieve Universal Access for all to HIV prevention, treatment, care ...
... research has found that turning cancer cells into mini ... efficient. ,Researchers from the University of New ... Albuquerque have found that these nanoparticles could make biopsies ... need to repeat these invasive tests. ...
... that surrounds the axons of nerve cells is attacked by ... nerve impulses and, ultimately, axon loss . ,Myelin ... sheath and when used as an antigen will induce experimental ... animal model of human MS. ,Interestingly, myelin-specific T ...
... has developed a drug that is more effective in ... . ,The drug also costs less than ... reported The Himalayan Times daily.Doctors at the Patan Hospital ... ,,The team compared the effectiveness of "Cefixime", ...
... is back to the levels of 20 years ago is ... it once was and homosexuals are consequently less afraid of ... in Melbourne in which a 48-year-old was charged with deliberately ... that something more nefarious is at work. ,,The Age ...
Cached Medicine News:Health News:Senior Church Leaders in Lesotho Pledge to Fight AIDS 2Health News:New Nano-power Could Make Biopsies Sensitive and Efficient 2Health News:Autoimmune Response in Multiple Sclerosis 2
... an OraSure HIV-1 Oral Specimen Collection Device is ... for HIV-1 antibodies. Testing with the OraSure HIV-1 ... needles and has been shown to be more ... specially treated cotton fiber pad attached to a ...
... benefits of TiMAX material have been applied to ... strength and an ultra-low profile combine to provide ... lower extremity. , ,This complete set of periarticular ... , Fibula Composite Plate , ...
The DePuy ACE Titanium Active Compression Plate offers ingenuity in the art of fracture management....
Corneal Marking Pen - Sterile. 10 pieces/box...
Medicine Products: